Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $62.16 million. The enterprise value is $48.50 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 75.35 million shares outstanding. The number of shares has increased by 23.11% in one year.
| Current Share Class | 75.35M |
| Shares Outstanding | 75.35M |
| Shares Change (YoY) | +23.11% |
| Shares Change (QoQ) | +44.91% |
| Owned by Insiders (%) | 0.47% |
| Owned by Institutions (%) | 16.55% |
| Float | 61.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.07 |
| Forward PS | 10.35 |
| PB Ratio | 2.95 |
| P/TBV Ratio | 3.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.84, with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.84 |
| Quick Ratio | 1.78 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -52.25 |
Financial Efficiency
Return on equity (ROE) is -149.03% and return on invested capital (ROIC) is -66.52%.
| Return on Equity (ROE) | -149.03% |
| Return on Assets (ROA) | -55.47% |
| Return on Invested Capital (ROIC) | -66.52% |
| Return on Capital Employed (ROCE) | -224.80% |
| Revenue Per Employee | $226,512 |
| Profits Per Employee | -$992,049 |
| Employee Count | 41 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.45% in the last 52 weeks. The beta is 2.03, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | -47.45% |
| 50-Day Moving Average | 1.01 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 48.42 |
| Average Volume (20 Days) | 224,598 |
Short Selling Information
The latest short interest is 851,924, so 1.13% of the outstanding shares have been sold short.
| Short Interest | 851,924 |
| Short Previous Month | 859,887 |
| Short % of Shares Out | 1.13% |
| Short % of Float | 1.39% |
| Short Ratio (days to cover) | 5.68 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $9.29 million and -$40.67 million in losses. Loss per share was -$0.72.
| Revenue | 9.29M |
| Gross Profit | -27.01M |
| Operating Income | -41.59M |
| Pretax Income | -49.97M |
| Net Income | -40.67M |
| EBITDA | -41.20M |
| EBIT | -41.59M |
| Loss Per Share | -$0.72 |
Full Income StatementBalance Sheet
The company has $23.39 million in cash and $8.88 million in debt, giving a net cash position of $14.51 million or $0.19 per share.
| Cash & Cash Equivalents | 23.39M |
| Total Debt | 8.88M |
| Net Cash | 14.51M |
| Net Cash Per Share | $0.19 |
| Equity (Book Value) | 17.50M |
| Book Value Per Share | 0.28 |
| Working Capital | 11.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$36.33 million and capital expenditures -$66,000, giving a free cash flow of -$36.40 million.
| Operating Cash Flow | -36.33M |
| Capital Expenditures | -66,000 |
| Free Cash Flow | -36.40M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | -290.82% |
| Operating Margin | -447.86% |
| Pretax Margin | -437.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.11% |
| Shareholder Yield | -23.11% |
| Earnings Yield | -64.55% |
| FCF Yield | -57.76% |
Analyst Forecast
The average price target for Cue Biopharma is $3.00, which is 263.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 263.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -1.08% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cue Biopharma has an Altman Z-Score of -15.38 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.38 |
| Piotroski F-Score | 3 |